Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3214-3223

  Koon, Hon Wai ^a   Shih, David Q ^b   Hing, Tressia C ^a   Yoo, Jun Hwan ^a,c   Ho, Samantha ^a   Chen, Xinhua ^d   Kelly, Ciarán P ^d   Targan, Stephan R ^b   Pothoulakis, Charalabos ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Ajou University School of Medicine   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MK 3415; MONOCLONAL ANTIBODY MK 6072; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CELLS, CULTURED; CLOSTRIDIUM DIFFICILE; COLON; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; PHOSPHORYLATION; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879028884     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02633-12     Document Type: Article

References (36)

1. Kelly CP. 2012. Current strategies for management of initial Clostridium difficile infection. J. Hosp. Med. 7(Suppl 3):S5-S10.
2. Kelly CP, LaMont JT. 2008. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359:1932-1940.
3. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis C. 2003. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-420. (Pubitemid 36929422)
4. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, Cosentini E, Feil W, Schiessel R, LaMont JT. 1995. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J. Clin. Invest. 95:2004-2011.
5. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
6. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713.
7. He D, Sougioultzis S, Hagen S, Liu J, Keates S, Keates AC, Pothoulakis C, Lamont JT. 2002. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology 122:1048-1057. (Pubitemid 34267287)
8. Na X, Zhao D, Koon HW, Kim H, Husmark J, Moyer MP, Pothoulakis C, LaMont JT. 2005. Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes. Gastroenterology 128:1002-1011. (Pubitemid 40523550)
9. Flegel WA, Muller F, Daubener W, Fischer HG, Hadding U, Northoff H. 1991. Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect. Immun. 59:3659-3666.
10. Warny M, Keates AC, Keates S, Castagliuolo I, Zacks JK, Aboudola S, Qamar A, Pothoulakis C, LaMont JT, Kelly CP. 2000. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J. Clin. Invest. 105:1147-1156. (Pubitemid 30217700)
11. Jefferson KK, Smith MF, Jr, Bobak DA. 1999. Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J. Immunol. 163:5183-5191.
12. Kim JM, Lee JY, Yoon YM, Oh YK, Youn J, Kim YJ. 2006. NF-kappa B activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with Clostridium difficile toxin A. Scand. J. Immunol. 63:453-460. (Pubitemid 43978860)
13. Chen X, Fruehauf J, Goldsmith JD, Xu H, Katchar KK, Koon HW, Zhao D, Kokkotou EG, Pothoulakis C, Kelly CP. 2009. Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology 137:914-923.
14. Kim H, Rhee SH, Kokkotou E, Na X, Savidge T, Moyer MP, Pothoulakis C, LaMont JT. 2005. Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J. Biol. Chem. 280: 21237-21245. (Pubitemid 40805686)
15. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, Bartlett JG. 1983. Serum antibody response to toxins A and B of Clostridium difficile. J. Infect. Dis. 148:93-100. (Pubitemid 13039317)
16. Aronsson B, Granstrom M, Mollby R, Nord CE. 1985. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 13:97-101. (Pubitemid 15030800)
17. Johnson S, Gerding DN, Janoff EN. 1992. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J. Infect. Dis. 166:1287-1294.
18. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397. (Pubitemid 30084537)
19. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193. (Pubitemid 32108091)
20. Kelly CP, Pothoulakis C, Vavva F, Castagliuolo I, Bostwick EF, O'Keane JC, Keates S, LaMont JT. 1996. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob. Agents Chemother. 40:373-379. (Pubitemid 26049350)
21. Kink JA, Williams JA. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 66:2018-2025. (Pubitemid 28194097)
22. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-6347. (Pubitemid 44657416)
23. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205.
24. Pothoulakis C, LaMont JT, Eglow R, Gao N, Rubins JB, Theoharides TC, Dickey BF. 1991. Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J. Clin. Invest. 88:119-125.
25. Hing TC, Ho S, Shih DQ, Ichikawa R, Cheng M, Chen J, Chen X, Law I, Najarian R, Kelly CP, Gallo RL, Targan SR, Pothoulakis C, Koon HW. 3 July 2012. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut [Epub ahead of print.] doi:10.1136/gutjnl-2012-302180.
26. Koon HW, Shih D, Karagiannides I, Zhao D, Fazelbhoy Z, Hing T, Xu H, Lu B, Gerard N, Pothoulakis C. 2010. Substance P modulates colitisassociated fibrosis. Am. J. Pathol. 177:2300-2309.
27. Pothoulakis C, Castagliuolo I, LaMont JT, Jaffer A, O'Keane JC, Snider RM, Leeman SE. 1994. CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc. Natl. Acad. Sci. U. S. A. 91:947-951. (Pubitemid 24048485)
28. Linevsky JK, Pothoulakis C, Keates S, Warny M, Keates AC, Lamont JT, Kelly CP. 1997. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am. J. Physiol. 273:G1333-G1340.
29. Warny M, Kelly CP. 1999. Monocytic cell necrosis is mediated by potassium depletion and caspase-like proteases. Am. J. Physiol. 276:C717-C724. (Pubitemid 29157389)
30. Rocha MF, Maia ME, Bezerra LR, Lyerly DM, Guerrant RL, Ribeiro RA, Lima AA. 1997. Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect. Immun. 65:2740-2746. (Pubitemid 27264102)
31. Lee JY, Kim H, Cha MY, Park HG, Kim YJ, Kim IY, Kim JM. 2009. Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK, and the NF-kappaB signaling pathway. J. Mol. Med. (Berl.) 87:169-180.
32. Gerding DN, Johnson S. 2011. Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI. Nat. Rev. Gastroenterol. Hepatol. 8:67-68.
33. Saito T, Kimura S, Tateda K, Mori N, Hosono N, Hayakawa K, Akasaka Y, Ishii T, Sumiyama Y, Kusachi S, Nagao J, Yamaguchi K. 2011. Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice. J. Antimicrob. Chemother. 66:1096-1099.
34. Salcedo J, Keates S, Pothoulakis C, Warny M, Castagliuolo I, LaMont JT, Kelly CP. 1997. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41:366-370. (Pubitemid 27428197)
35. Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT, Pothoulakis C, Kelly CP. 1999. Bovine immunoglobulin concentrate-Clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 44:212-217. (Pubitemid 29119364)
36. Kelly CP, Kyne L. 2011. The host immune response to Clostridium difficile. J. Med. Microbiol. 60:1070-1079.